PharmaMar Has Announced That the Spanish Medicines Agency Has Authorized the APLICOV-PC Clinical Trial With Aplidin® (Plitidepsin) for the Treatment of Patients With COVID-19
- The objective of the trial is to evaluate the efficacy and safety of plitidepsin in patients with COVID-19 requiring hospital admission - Plitidepsin recently obtained positive results from in vitro studies on the human HCoV-229E coronavirus, carried out at the National Biotechnology Center (C...
2020-04-28 18:57
4054
PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates
MADRID, Feb. 14, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics receives exclusive worldwide rights to certain PharmaMar proprietary molecules for the developme...
2018-02-14 21:30
2369
